Science and Technology · Medical Science

With reference to inhaled nitric oxide (iNO) therapy and antimicrobial resistance, consider the following statements: I. High-dose inhaled nitric oxide has shown antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa in large-animal ICU models. II. Nitric oxide used clinically at low doses primarily acts as a selective pulmonary vasodilator without direct antibacterial action. III. High-dose inhaled nitric oxide therapy is already a widely adopted standard-of-care treatment for drug-resistant pneumonia in ICUs globally. IV. Widespread clinical adoption of high-dose inhaled nitric oxide faces feasibility constraints due to delivery infrastructure and toxicity monitoring requirements. Which of the above statements are correct?